Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene.
Post-translational
Auto-ubiquitinates in an E2-dependent manner leading to its own degradation. Also polyubiquitinated by RNF41 for proteasomal degradation.
S-nitrosylated. The inhibition of PARK2 ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PARK2 substrates.
宿主种属
兔(Rabbit)
特异性
PRKN
种属反应性
人(Human),大鼠(Rat),小鼠(Mouse)
免疫原
A synthetic peptide derived from human Parkin (AA 5-56).
阳性对照
WB: Jurkat, HEK293, K562 and NIH/3T3 cell lysates. IF/ICC: HeLa cells.
Recombinant Parkin Antibody (Ab120363) - Western Blot All lanes: Recombinant Parkin Antibody (Ab120363) at 1/1000 dilution Samples: Lysates at 20 µg per lane Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution Predicted band size: 52 kDa Observed band size: 52, 48 kDa Parkin has 8 isoforms produced by alternative splicing with molecular weights of 24, 31, 36 and 42 - 52 kDa. Exposure time: 36.8 s
Recombinant Parkin Antibody (Ab120363) - Western Blot All lanes: Recombinant Parkin Antibody (Ab120363) at 1/1000 dilution Samples: Lysates at 20 µg per lane Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/30000 dilution Predicted band size: 52 kDa Observed band size: 48 kDa Parkin has 8 isoforms produced by alternative splicing with molecular weights of 24, 31, 36 and 42 - 52 kDa. Exposure time: 60.0 s
Recombinant Parkin Antibody (Ab120363) - IF/ICC Immunofluorescent analysis of HeLa cells, using Recombinant Parkin Antibody (Ab120363) at 1/50 dilution.
Recombinant Parkin Antibody (Ab120363) - IF/ICC Immunofluorescent analysis of HeLa cells, using Recombinant Parkin Antibody (Ab120363) at 1/150 dilution.
ZJ24F0910205
危险品化学品经营许可证（带存储）